NASDAQ:AKTX

Akari Therapeutics (AKTX) Stock Forecast, Price & News

$0.18

-0.01 (-5.35%)

(As of 05/31/2023 ET)

Compare

Today's Range: $0.18
▼
$0.19
50-Day Range: $0.15
▼
$0.26
52-Week Range: $0.14
▼
$1.61

Volume: 219,876 shs
Average Volume: 353,666 shs
Market Capitalization: $13.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $2.75

Akari Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,454.6% Upside
$2.75 Price Target
Short Interest: Healthy
0.31% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.48
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

678th out of 1,006 stocks

Pharmaceutical Preparations Industry

345th out of 492 stocks

3.5

Analyst's Opinion

Consensus Rating
Akari Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.75, Akari Therapeutics has a forecasted upside of 1,454.6% from its current price of $0.18.
Amount of Analyst Coverage
Akari Therapeutics has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.31% of the outstanding shares of Akari Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Akari Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Akari Therapeutics has recently increased by 104.47%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Akari Therapeutics does not currently pay a dividend.
Dividend Growth
Akari Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AKTX.

2.5

News and Social Media Coverage

News Sentiment
Akari Therapeutics has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Akari Therapeutics this week, compared to 1 article on an average week.
Search Interest
4 people have searched for AKTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Akari Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Akari Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
61.80% of the stock of Akari Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 13.59% of the stock of Akari Therapeutics is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Akari Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Akari Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Akari Therapeutics has a P/B Ratio of 8.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Akari Therapeutics (NASDAQ:AKTX) Stock

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Stock News Headlines

May 27, 2023 | americanbankingnews.com

Akari Therapeutics, Plc (NASDAQ:AKTX) Sees Significant Increase in Short Interest

May 26, 2023 | americanbankingnews.com

Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com

June 1, 2023 | Vantage Point (Ad)

We Called (ARWR) In Advance, Which Stocks Are Next?

Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.

May 18, 2023 | americanbankingnews.com

Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated at StockNews.com

May 16, 2023 | finance.yahoo.com

Akari Therapeutics to Participate in A.G.P.’s Virtual Healthcare Conference

May 12, 2023 | americanbankingnews.com

Akari Therapeutics, Plc (NASDAQ:AKTX) Sees Large Decrease in Short Interest

May 9, 2023 | americanbankingnews.com

Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.com

May 1, 2023 | finance.yahoo.com

Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights

June 1, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.

May 1, 2023 | finance.yahoo.com

Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights

April 25, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement

April 25, 2023 | finance.yahoo.com

Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement

April 23, 2023 | americanbankingnews.com

Akari Therapeutics (NASDAQ:AKTX) Receives New Coverage from Analysts at StockNews.com

April 19, 2023 | finance.yahoo.com

Insiders rewarded with a US$607k addition on top of their US$1.3m purchase as Akari Therapeutics, Plc (NASDAQ:AKTX) hits US$22m

April 18, 2023 | americanbankingnews.com

Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Update

April 14, 2023 | finance.yahoo.com

Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs

April 11, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology

April 11, 2023 | finance.yahoo.com

Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology

April 3, 2023 | finance.yahoo.com

Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting

March 31, 2023 | msn.com

European Equities Close Out Strong Week Higher in Friday Trading

March 30, 2023 | msn.com

European Equities Rally in Thursday Trading

March 30, 2023 | benzinga.com

Akari Therapeutics Stock (NASDAQ:AKTX), Dividends

March 30, 2023 | finanznachrichten.de

Akari Therapeutics Plc: Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering

March 30, 2023 | finance.yahoo.com

Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering

March 30, 2023 | americanbankingnews.com

Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com

March 29, 2023 | finance.yahoo.com

Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study

March 27, 2023 | msn.com

Bank Stock Recovery Supports American Depositary Receipts of European Equities

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Company Calendar

Last Earnings: 3/31/2020
Today: 5/31/2023
Next Earnings (Estimated): 7/19/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AKTX
CUSIP: N/A
CIK: 1541157
Web: www.akaritx.com
Phone: 442080040261
Fax: 646-843-9352
Employees: 9
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $2.75
High Stock Price Forecast: $4.00
Low Stock Price Forecast: $1.50
Forecasted Upside/Downside: +1,454.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.15
Quick Ratio: 1.15

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.02 per share
Price / Book: 8.85

Miscellaneous

Outstanding Shares: 74,450,000
Free Float: 28,440,000
Market Cap: $13.17 million
Optionable: Not Optionable
Beta: 1.31

Key Executives

Rachelle Jacques
President, Chief Executive Officer & Director

Melissa Bradford-Klug
Chief Operating Officer

Torsten Hombeck
Chief Financial & Accounting Officer

Miles Nunn
Chief Scientific Officer

John F. Neylan
Chief Medical Officer & Executive Vice President

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

AKTX Stock - Frequently Asked Questions

Should I buy or sell Akari Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AKTX shares.
View AKTX analyst ratings or view top-rated stocks.
What is Akari Therapeutics' stock price forecast for 2023?: 2 Wall Street research analysts have issued twelve-month price targets for Akari Therapeutics' stock. Their AKTX share price forecasts range from $1.50 to $4.00. On average, they anticipate the company's share price to reach $2.75 in the next twelve months. This suggests a possible upside of 1,454.6% from the stock's current price.
View analysts price targets for AKTX or view top-rated stocks among Wall Street analysts.
How have AKTX shares performed in 2023?: Akari Therapeutics' stock was trading at $0.4699 at the start of the year. Since then, AKTX shares have decreased by 62.4% and is now trading at $0.1769.
View the best growth stocks for 2023 here.
Are investors shorting Akari Therapeutics?: Akari Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 228,600 shares, an increase of 104.5% from the April 30th total of 111,800 shares. Based on an average trading volume of 485,100 shares, the days-to-cover ratio is presently 0.5 days.
View Akari Therapeutics' Short Interest.
When is Akari Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 19th 2023.
View our AKTX earnings forecast.
How were Akari Therapeutics' earnings last quarter?: Akari Therapeutics, Plc (NASDAQ:AKTX) issued its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.25.

What other stocks do shareholders of Akari Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Akari Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Biocept (BIOC), OPKO Health (OPK), Anavex Life Sciences (AVXL), Rigel Pharmaceuticals (RIGL), Teva Pharmaceutical Industries (TEVA), Vascular Biogenics (VBLT) and Heat Biologics (HTBX).
What is Akari Therapeutics' stock symbol?: Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."
Who are Akari Therapeutics' major shareholders?: Akari Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (10.67%) and Renaissance Technologies LLC (0.38%).
View institutional ownership trends.
How do I buy shares of Akari Therapeutics?: Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Akari Therapeutics' stock price today?: One share of AKTX stock can currently be purchased for approximately $0.18.
How much money does Akari Therapeutics make?: Akari Therapeutics (NASDAQ:AKTX) has a market capitalization of $13.17 million. The biopharmaceutical company earns $-17,750,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.
How can I contact Akari Therapeutics?: Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The official website for the company is www.akaritx.com. The biopharmaceutical company can be reached via phone at 442080040261, via email at info@akaritx.com, or via fax at 646-843-9352.

This page (NASDAQ:AKTX) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial